Investors & News / Media Coverage / Media Coverage Year None202420222020201920172016 Jul 18, 2024 Lisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy research Jul 17, 2024 BioHub Podcast with Dr. David Mazzo, CEO of Lisata Therapeutics Jul 16, 2024 Lisata Therapeutics completes enrollment in Phase 2a BOLSTER trial for certepetide in bile duct cancer Jul 13, 2024 Lisata’s certepetide showing promising early results as cholangiocarcinoma treatment – ICYMI Jul 11, 2024 Lisata’s Certepetide: promising preclinical results in cholangiocarcinoma Jul 08, 2024 Lisata Therapeutics embarks on cancer-fighting campaign Jun 07, 2024 Pharma’s R&D gamble: picking pipeline winners in a risky field May 29, 2024 How does Lisata Therapeutics have a negative enterprise value? May 10, 2024 Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results Apr 23, 2024 Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Print Page RSS Feeds Email Alerts
Year None202420222020201920172016 Jul 18, 2024 Lisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy research Jul 17, 2024 BioHub Podcast with Dr. David Mazzo, CEO of Lisata Therapeutics Jul 16, 2024 Lisata Therapeutics completes enrollment in Phase 2a BOLSTER trial for certepetide in bile duct cancer Jul 13, 2024 Lisata’s certepetide showing promising early results as cholangiocarcinoma treatment – ICYMI Jul 11, 2024 Lisata’s Certepetide: promising preclinical results in cholangiocarcinoma Jul 08, 2024 Lisata Therapeutics embarks on cancer-fighting campaign Jun 07, 2024 Pharma’s R&D gamble: picking pipeline winners in a risky field May 29, 2024 How does Lisata Therapeutics have a negative enterprise value? May 10, 2024 Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results Apr 23, 2024 Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last »
Jul 18, 2024 Lisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy research
Jul 16, 2024 Lisata Therapeutics completes enrollment in Phase 2a BOLSTER trial for certepetide in bile duct cancer
Jul 13, 2024 Lisata’s certepetide showing promising early results as cholangiocarcinoma treatment – ICYMI
May 10, 2024 Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results